- Home
- Equipment
- north america
- clinical proof
Refine by
Clinical Proof Equipment Supplied In North America
10 equipment items found
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
The disease can also affect the lining of the mouth, esophagus, eye, anus and vagina. BridgeBio completed a Phase 2 clinical trial evaluating safety and tolerability of PTR-01, as well as clinical proof of concept, and has initiated a Phase 2 extension ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
In mouse models of achondroplasia, infigratinib demonstrated robust bone growth and clear improvement in cranial and spinal defects. BridgeBio is currently conducting a Phase 2 clinical trial in achondroplasia patients to evaluate the safety and tolerability of low-dose infigratinib, as well as clinical ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
Manufactured by:CyberKnife, by Accuray Incorporated based inMadison, WISCONSIN (USA)
CyberKnife treatments are typically performed in 1 to 5 sessions. The CyberKnife System has more than two decades of clinical proof and has helped thousands of cancer ...
Manufactured by:Pain Care Labs based inAtlanta, GEORGIA (US) (USA)
Buzzy Mini Healthcare features a contoured and compact design that tucks under a standard tourniquet or fits easily in the hand to deliver powerful pain blocking right where you need it. Patented M-Stim™ mechanical stimulation and ice technology blocks pain on contact. Intended for healthcare and multi-patient use, or those that desire a healthcare grade unit. Features 3 minute auto-shutoff ...
Manufactured by:BiomX based inNess Ziona, ISRAEL
BiomX develops phage cocktails (or combinations) that target and kill specific pathogenic bacteria. Our phage cocktails, which are optimized through algorithms and experimental validation (in-vitro and in-vivo), contain multiple natural and/or engineered phage. The phage are selected to have complementary functions such as wide target bacterial host range and the ability to avoid the development ...
Manufactured by:Cellanyx, LLC based inBeverly, MASSACHUSETTS (USA)
Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no metastatic potential. There are two sub types – Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). The incidence of these entities is ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
RTX (resiniferatoxin) is a unique neural intervention molecule that is highly selective and may be applied peripherally (e.g., nerve block, intra-articular) or centrally (e.g., epidural), to control chronic pain across multiple conditions including arthritis and cancer. RTX has the potential to be a first-in-class drug addressing currently intractable pain in a novel and unique way, by targeting ...
Manufactured by:Vaxcyte, Inc. based inSan Carlos, CALIFORNIA (USA)
We believe our clinical-stage company is uniquely positioned to create vaccines that can overcome bacteria’s formidable defense mechanisms and be produced on a significant scale. We are leveraging our XpressCF™ cell-free protein synthesis platform to create high-fidelity vaccines featuring distinct protein carriers and antigens – the critical building blocks of vaccines ...
Manufactured by:Ascelia Pharma AB based inMalmö, SWEDEN
Oncoral is a novel daily irinotecan chemotherapy in development. Irinotecan chemotherapy has an established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily irinotecan tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following ...